Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Taiwan Yi Xue Hui Za Zhi. Journal of the Formosan Medical Association|February 1, 1989
Bone marrow involvement in non-Hodgkin's lymphomaH S Lai, H F Tien, H C Hsieh, et al.
Blood Cancer Journal|June 21, 2014
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivityS-H Kuo, K-H Yeh, L-T Chen, et al.
British Journal of Cancer|May 20, 2004
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tractC Hsu, Y-C Shen, C-H Yang, et al.
Breast Cancer Research and Treatment|October 17, 1998
High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancersK H Yeh, M T Lin, D T Lin, et al.
Blood Cancer Journal|July 16, 2013
Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significanceS-H Kuo, L-T Chen, C-W Lin, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2015
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsT C Chang, H S Shiah, C H Yang, et al.
British Journal of Cancer|July 1, 2004
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancerY Chao, K H Yeh, C J Chang, et al.
The Journal of Pathology|December 15, 2006
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expressionS-H Kuo, L-T Chen, M-S Wu, et al.
Blood Cancer Journal|October 11, 2014
Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphomaF Liao, Y-C Hsu, S-H Kuo, et al.
British Journal of Cancer|April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesC-C Lin, W-C Su, C-J Yen, et al.
Pageof 12